<DOC>
	<DOCNO>NCT01347983</DOCNO>
	<brief_summary>24 week open-labeled extension study continue monitor group patient previous MRA230TW phase IIIb trial order evaluate long term efficacy safety tocilizumab .</brief_summary>
	<brief_title>Extension Study Tocilizumab Long Term Treatment Moderate Severe Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients complete least 5 7 visit schedule week 2 , 4 , 8 , 12 , 16 , 20 24 tocilizumab Phase IIIb study ( MRA230TW ) . Patients assign Phase IIIb study ( MRA230TW ) , receive schedule dose least 16 week still fail achieve adequate treatment response characterize ACR20 Patients receive major surgery include joint surgery 8 week prior screen schedule operate within 6 month enrolment . Patients rheumatoid autoimmune disease RA , include limited SLE ( system lupus erythematosus ) , significant systemic involvement secondary RA . Patients belong Class IV ACR classification criterion functional status RA . ( ACR Amended Criteria Classification Functional Capacity Rheumatoid Arthritis ; Class IV : Largely wholly incapacitated patient bedridden confine wheel chair , permit little selfcare ) . Patients history hypersensitivity human , humanize murine monoclonal antibody patient contraindication . Patients currently history recurrence bacterial , viral , fungal , mycobacterial infection infectious disease ; tuberculosis ( TB ) , atypical mycobacterial disease , clinically significant granulomatous disease chest radiograph , hepatitis B , hepatitis C , herpes zoster etc . However , patient hand &amp; foot fungal infection participate .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>RA</keyword>
</DOC>